Modena of the United States announced on October 17 that it will strive to launch a combination vaccine against COVID-19 and seasonal influenza in Japan by 2027. CEO Stefan Bansell said that the materials are being prepared to be submitted to Japan's Ministry of Health, Labor, and Welfare, and he hopes it will take about half a year to a year to submit the application. According to the company, if the vaccine being developed can be applied in practice, two types of immunity can be obtained with a single vaccination, which is expected to reduce the burden on medical institutions and vaccinators. The company's COVID-19 vaccine used in Japan is an imported vaccine manufactured overseas.

Modena of the United States announced on October 17 that it will strive to launch a combination vaccine against COVID-19 and seasonal influenza in Japan by 2027. CEO Stefan Bansell said that the materials are being prepared to be submitted to Japan's Ministry of Health, Labor, and Welfare, and he hopes it will take about half a year to a year to submit the application. According to the company, if the vaccine being developed can be applied in practice, two types of immunity can be obtained with a single vaccination, which is expected to reduce the burden on medical institutions and vaccinators. The company's COVID-19 vaccine used in Japan is an imported vaccine manufactured overseas.